Question 1

What is David Berz?

Accepted Answer

David Berz is a Person.

Question 2

How often does David Berz appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 33 articles.

Question 3

When was David Berz first tracked by Ergen?

Accepted Answer

First tracked on May 25, 2026.

Question 4

When was David Berz last mentioned in news?

Accepted Answer

Last active on Jun 08, 2026.

Question 5

What is David Berz's current news sentiment?

Accepted Answer

Aggregate sentiment score: 0 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is David Berz in global news coverage?

Accepted Answer

Attention score of 7, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving David Berz?

Accepted Answer

ASCO 2026 Oncology Research Presentations (May 25, 2026, 33 articles).

Question 8

How did the "ASCO 2026 Oncology Research Presentations" event impact David Berz?

Accepted Answer

David Berz, MD, PhD, from Valkyrie Clinical Trials, Inc, is the first author for an international multicenter Phase II study of ivonescimab in metastatic colorectal cancer.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.